The pharmaceutical industry stands at the threshold of a transformative era where artificial intelligence is fundamentally reshaping how new medicines are discovered, developed, and brought to market. As the global AI in drug discovery market surges from USD 1.98 billion in 2024 toward a projected USD 20.31 billion by 2034, representing a compound annual growth rate of 26.21 percent, the Middle East is positioning itself to capture a significant share of this revolutionary advancement. This technological leap promises to address one of the pharmaceutical industry’s most persistent challenges: the traditionally lengthy, costly, and often inefficient process of bringing new drugs from laboratory concept to patient bedside.

Traditional drug discovery has long been characterized by its demanding nature, typically requiring over a decade and exceeding USD 2 billion in investment to bring a single drug to market. The attrition rate remains staggeringly high, with nearly 90 percent of drug candidates failing due to insufficient efficacy or unforeseen safety concerns. Against this backdrop, AI in drug discovery emerges not merely as an incremental improvement but as a fundamental reimagining of pharmaceutical research and development. Machine learning algorithms can now analyze vast amounts of biological and chemical data in a fraction of the time previously required, identifying potential drug candidates with unprecedented speed and accuracy.

The Technological Foundation of AI in Drug Discovery

At its core, AI in drug discovery leverages multiple sophisticated technologies working in concert to accelerate and improve pharmaceutical development. Machine learning algorithms form the backbone of this transformation, enabling researchers to analyze complex biological systems and predict molecular interactions with remarkable precision. Deep learning techniques, particularly neural networks, have proven especially valuable in identifying patterns within genomics and proteomics data that would be virtually impossible for human researchers to discern manually.

The integration of AI into drug discovery encompasses several critical applications. Virtual screening capabilities allow researchers to evaluate millions of chemical compounds rapidly, dramatically reducing the number of compounds that require physical synthesis and laboratory testing. This computational approach to screening has proven particularly effective, with recent studies demonstrating that AI platforms can identify structurally novel hits for a substantial majority of evaluated targets. The technology shifts drug discovery away from serendipitous discovery toward structure-based search, making the entire process more rational, effective, and efficient.

Natural language processing represents another crucial component of AI drug discovery platforms, enabling systems to synthesize vast amounts of scientific literature and extract relevant insights for ongoing research projects. This capability proves invaluable when researchers need to understand disease mechanisms or identify potential drug-disease associations from the expanding corpus of biomedical literature. The ability to aggregate and synthesize information automatically accelerates the hypothesis formation and qualification stages that traditionally consumed substantial researcher time and effort.

Transforming Target Identification and Validation

The journey of drug discovery begins with target identification, where researchers must determine which biological molecules or pathways to address with potential therapeutics. AI has revolutionized this foundational stage by enabling comprehensive analysis of genomic, proteomic, and metabolomic data to identify disease-associated targets with far greater precision than traditional methods allowed. Machine learning models can now integrate data from multiple sources, including genetic studies, clinical databases, and experimental results, to predict which targets hold the greatest therapeutic promise for specific diseases.

Beyond simple identification, AI excels at predicting how potential drug candidates will interact with biological targets. These predictive capabilities stem from sophisticated algorithms trained on extensive datasets of known drug-target interactions, molecular structures, and biological activity profiles. By evaluating structural and chemical properties of both targets and potential drug molecules, AI systems can forecast binding affinities and likely therapeutic effects before researchers commit resources to laboratory synthesis and testing. This predictive power significantly reduces the risk of pursuing ineffective drug candidates through expensive development pipelines.

The validation stage, which confirms that modulating a specific target will produce desired therapeutic effects without unacceptable side effects, also benefits tremendously from AI capabilities. Machine learning models can analyze data from previous research and clinical trials to forecast the effectiveness of targeting specific biological molecules and assess the probability of adverse effects manifesting during later development stages. This early-stage risk assessment enables pharmaceutical companies to make more informed decisions about which programs to advance, substantially improving resource allocation and increasing the overall success rate of drug development portfolios.

Accelerating Lead Discovery and Optimization

Once viable targets have been identified, the drug discovery process moves into lead discovery, where researchers search for chemical compounds that effectively modulate the target. AI dramatically accelerates this phase through generative models capable of designing novel molecular structures specifically optimized for desired properties. These AI systems can propose millions of synthesizable compounds that traditional medicinal chemistry approaches would never have considered, vastly expanding the chemical space available for exploration.

The optimization of lead compounds represents one of AI drug discovery’s most compelling applications. After initial hits are identified, they typically require extensive modification to improve properties such as potency, selectivity, bioavailability, and safety. Machine learning algorithms can predict how specific structural modifications will affect these properties, enabling researchers to prioritize the most promising chemical modifications and reduce the number of synthesis-test cycles required. Recent advances have demonstrated that AI-driven approaches can achieve development timelines measured in months rather than years for progressing from initial hits to development candidates.

Pharmaceutical companies are increasingly adopting AI platforms that incorporate deep learning for structure-based drug design, enabling rapid, AI-powered searches of proprietary libraries containing trillions of synthesizable compounds. These platforms can identify structurally novel hits for targets that previously proved intractable with conventional approaches. The technology proves particularly valuable for addressing challenging targets in areas such as oncology, immunology, and neuroscience, where traditional drug discovery methods have struggled to produce viable therapeutics.

Predicting Drug Properties and Reducing Development Risks

A critical advantage of AI in drug discovery lies in its ability to predict multiple drug properties simultaneously, including pharmacokinetics, toxicity, and off-target effects. These predictive capabilities enable researchers to identify potential problems before compounds enter expensive and time-consuming preclinical testing phases. Machine learning models trained on extensive datasets of known drug properties can forecast how new compounds will be absorbed, distributed, metabolized, and excreted in the body, allowing early optimization of drug-like properties.

Toxicity prediction represents an especially valuable application, as unexpected adverse effects discovered during clinical trials constitute a major cause of drug development failures. AI systems can analyze structural features of proposed compounds and compare them against databases of known toxicological profiles to flag potential safety concerns. This early warning system enables medicinal chemists to modify problematic structural elements before investing in full development programs, substantially reducing the risk of late-stage failures that can cost pharmaceutical companies hundreds of millions of dollars.

The ability to predict drug-drug interactions and off-target effects provides additional layers of risk mitigation. As patients often take multiple medications concurrently, understanding potential interactions becomes crucial for ensuring drug safety. Machine learning algorithms can identify potential interaction risks by analyzing how different compounds affect shared metabolic pathways or compete for the same biological targets. Similarly, predicting off-target effects helps researchers understand whether drug candidates might inadvertently affect biological systems beyond their intended targets, potentially causing side effects that would compromise therapeutic viability.

Streamlining Clinical Development and Personalized Medicine

The impact of AI in drug discovery extends beyond preclinical stages into clinical development, where intelligent systems optimize trial design, patient recruitment, and outcome prediction. Machine learning algorithms can analyze patient data to identify optimal trial populations, ensuring that clinical studies enroll participants most likely to demonstrate therapeutic responses. This capability proves especially valuable for trials involving rare diseases or specific patient subpopulations where recruitment challenges have historically delayed or prevented important studies.

Predictive modeling for clinical trial outcomes represents another frontier where AI demonstrates substantial value. By analyzing data from previous trials, patient characteristics, and molecular biomarkers, machine learning systems can forecast the likelihood of trial success and identify factors that might compromise outcomes. This predictive capability enables pharmaceutical companies to make data-driven decisions about which programs to advance into clinical testing and how to structure trials for optimal chances of demonstrating efficacy and safety.

The convergence of AI drug discovery with personalized medicine opens particularly exciting possibilities for the future of pharmaceutical development. As AI systems analyze individual patient genomic profiles, biomarkers, and clinical characteristics, they can identify which patients are most likely to respond to specific therapies and predict optimal dosing regimens. This capability moves medicine toward truly personalized treatment approaches, where therapeutic decisions are guided by comprehensive understanding of individual patient biology rather than population averages. The integration of real-world patient data from electronic health records and wearable devices further enhances this personalized approach, creating feedback loops that continuously improve therapeutic strategies.

The Middle East’s Strategic Position in AI Drug Discovery

The Middle East, particularly the Gulf region, has emerged as an increasingly important player in the global AI drug discovery landscape. The opening of major AI-powered biotechnology research centers in Abu Dhabi signals the region’s commitment to becoming a hub for pharmaceutical innovation. These facilities combine global talent in artificial intelligence and software development with state-of-the-art computational infrastructure to develop and deploy cutting-edge drug discovery platforms.

Regional advantages position the Middle East favorably for AI drug discovery leadership. The combination of substantial financial resources, progressive economic policies, and strategic government support creates an environment conducive to biotechnology innovation. Abu Dhabi’s location in the International Renewable Energy Agency headquarters at Masdar City, for instance, provides access to sustainable infrastructure while positioning research centers within a broader innovation ecosystem. The compact geographical footprint of Gulf states facilitates rapid collaboration among key stakeholders, from academic institutions to pharmaceutical companies to healthcare providers.

Investment in digital health ecosystems throughout the Middle East further amplifies the region’s AI drug discovery potential. The proliferation of wearable technology and mobile health applications generates vast streams of real-world patient data that can feed AI drug discovery platforms. This data proves invaluable for understanding disease progression, identifying patient populations for clinical trials, and validating therapeutic approaches in diverse populations. The region’s genomic research initiatives, including national genome programs, create additional datasets that enhance AI capabilities for developing personalized medicines tailored to regional genetic profiles.

The Middle East also benefits from its position as a bridge between established pharmaceutical markets in Europe and North America and rapidly growing markets across Asia and Africa. This geographical advantage, combined with improving regulatory frameworks and increasing harmonization with international standards, positions the region as an attractive location for pharmaceutical companies seeking to develop drugs for global markets. The implementation of fast-track approval pathways for innovative medications, including biosimilars, further enhances the region’s appeal as a base for AI-driven drug discovery operations.

Overcoming Implementation Challenges

Despite its transformative potential, AI in drug discovery faces several challenges that must be addressed to realize its full promise. Data quality and availability represent fundamental concerns, as machine learning algorithms require extensive, high-quality datasets for training and validation. The pharmaceutical industry has historically struggled with data silos, inconsistent data formats, and limited data sharing between organizations. Addressing these challenges requires industry-wide collaboration to establish data standards, create shared databases, and develop frameworks for responsible data sharing that protect intellectual property while enabling collective advancement.

The interpretability of AI models poses another significant challenge, particularly in highly regulated industries like pharmaceuticals. Regulatory agencies and pharmaceutical companies need to understand how AI systems arrive at their predictions and recommendations to ensure safety and build trust. The development of explainable AI approaches that provide transparent reasoning for their outputs represents an active area of research with important implications for regulatory acceptance of AI-discovered drugs. Recent initiatives focus on creating AI systems that not only make predictions but also explain the biological and chemical rationale underlying their recommendations.

Integration of AI systems into existing pharmaceutical research and development workflows requires careful change management and workforce development. Scientists and pharmaceutical professionals need training to effectively leverage AI tools and interpret their outputs. Organizations must develop new processes that incorporate AI insights into decision-making while preserving the critical thinking and domain expertise that human researchers bring to drug discovery. This human-AI collaboration model, rather than AI replacement of human scientists, represents the most promising path forward for pharmaceutical innovation.

Regulatory frameworks continue to evolve to address the unique characteristics of AI-discovered drugs. Regulatory agencies worldwide are developing guidance documents and frameworks for evaluating drugs developed using artificial intelligence and machine learning. These evolving regulations aim to ensure that AI-discovered therapies meet rigorous safety and efficacy standards while not imposing unnecessary barriers that would slow innovation. The pharmaceutical industry’s engagement with regulators to shape appropriate oversight frameworks will prove crucial for enabling the responsible advancement of AI drug discovery.

Economic Impact and Industry Transformation

The economic implications of AI in drug discovery extend far beyond simple cost reduction, fundamentally transforming the economics of pharmaceutical development. The traditional model of drug discovery, with its high failure rates and lengthy timelines, has driven consolidation in the pharmaceutical industry as only the largest companies could bear the financial risks of modern drug development. AI’s ability to improve success rates, reduce development timelines, and lower costs could democratize drug discovery, enabling smaller biotechnology companies and academic institutions to compete effectively in therapeutic innovation.

Estimates suggest that comprehensive implementation of AI and related technologies could accelerate drug development by more than 500 days and reduce development costs by 25 percent. These improvements would have profound implications for pharmaceutical companies’ return on investment calculations and could enable development of drugs for smaller patient populations or diseases that previously lacked viable commercial markets. The technology particularly benefits development of therapies for rare diseases and precision medicines tailored to specific genetic profiles, areas where traditional development economics have often proven prohibitive.

The shift toward AI-driven drug discovery is fostering new business models and partnership structures within the pharmaceutical ecosystem. AI-focused biotechnology startups are forming strategic collaborations with large pharmaceutical companies, combining computational expertise with clinical development capabilities and market access. These partnerships often involve innovative deal structures where AI companies receive milestone payments and royalties based on successful drug approvals, aligning incentives and sharing risks between technology providers and pharmaceutical developers. Major pharmaceutical companies are establishing their own AI research groups while simultaneously investing in and partnering with AI drug discovery startups, creating a dynamic ecosystem of innovation.

Investment in AI drug discovery continues to accelerate despite broader economic uncertainties affecting the biotechnology sector. The recognition that AI represents not an optional enhancement but a competitive necessity drives pharmaceutical companies to increase their commitments to artificial intelligence and machine learning capabilities. This investment encompasses not only technology platforms and computing infrastructure but also talent acquisition, training programs, and organizational changes required to fully leverage AI capabilities across drug discovery operations.

Future Directions and Emerging Opportunities

The future trajectory of AI in drug discovery points toward increasingly sophisticated integration of multiple technologies and data sources. The convergence of AI with quantum computing promises to unlock new levels of computational power for molecular simulation and drug design, enabling more accurate predictions of drug-target interactions and chemical properties. While practical quantum computing for drug discovery remains in early stages, ongoing research suggests that quantum-classical hybrid approaches could provide near-term advantages for specific computational challenges in pharmaceutical research.

The integration of AI drug discovery platforms with digital twin technologies represents another frontier with significant potential. Digital twins of biological systems, from individual organs to complete patient profiles, could enable researchers to simulate drug effects in silico before conducting physical experiments. These virtual models, continuously updated with real-world patient data, would allow testing of therapeutic hypotheses and optimization of treatment regimens with unprecedented speed and precision. The combination of AI-designed drugs with digital twin testing platforms could dramatically accelerate the development of effective, safe therapies while reducing reliance on animal testing.

Multimodal AI systems that integrate diverse data types including text, images, molecular structures, and clinical data promise to provide more comprehensive understanding of disease mechanisms and therapeutic opportunities. These systems could analyze medical imaging, pathology slides, electronic health records, and genomic data simultaneously to identify disease biomarkers, predict therapeutic responses, and personalize treatment strategies. The development of large language models specifically trained on biomedical literature and pharmaceutical data is already beginning to transform how researchers access and synthesize scientific knowledge.

The evolution toward autonomous drug discovery systems represents perhaps the most ambitious vision for AI’s role in pharmaceutical research. These systems would integrate target identification, drug design, synthesis planning, and experimental validation into seamless workflows requiring minimal human intervention. While fully autonomous discovery remains years away, incremental progress toward this goal continues through the development of lab automation systems that can execute AI-designed experiments, analyze results, and iteratively refine therapeutic hypotheses. The combination of AI-driven decision-making with robotic laboratory automation creates feedback loops that accelerate the learning and optimization processes underlying drug discovery.

The Middle East’s continued investment in AI drug discovery infrastructure, combined with its strategic geographic position, growing life sciences ecosystem, and commitment to healthcare innovation, positions the region to play an increasingly important role in global pharmaceutical development. As AI technologies mature and regulatory frameworks evolve to accommodate AI-discovered drugs, the democratization of drug discovery capabilities could enable the region to become not merely a consumer of pharmaceutical innovations developed elsewhere but a generator of novel therapeutics addressing both regional and global health needs. This transformation from pharmaceutical importer to innovator represents a strategic opportunity with profound implications for economic development, healthcare outcomes, and scientific leadership across the Middle East.

With a compound annual growth rate (CAGR) of 22.4%, the present bioprocessing market is projected to be worth more than $218 million in 2023 and is expected to reach more than $599 million by 2028, according to one of the market research studies published. The main causes of this development are the rising demand for biopharmaceuticals, the increasing acceptance of continuous bioprocessing among contract manufacturing companies (CMOs) and contract manufacturing organisations (CMOs), and the benefits of continuous bioprocessing over batch and fed-batch modes of production.

Knowledge of Market Dynamics By use of PAT’s application to optimise continuous bioprocesses

Process analytical technology (PAT) is the name given to a system including analytical tools meant for monitoring and control of industrial processes. Apart from sensor technologies, tools for process analysis and testing (PAT) such as spectroscopy and chromatography enable continuous monitoring of important process parameters (CPPs) and critical quality attributes (CQAs) in real time. This helps manufacturers to quickly spot any kind of deviation and implement the required corrections to maintain the integrity of the process as well as the quality of the goods. The PAT advances and helps the producers maximise their operations in several spheres, including the following:

Process knowledge and control: PAT helps to deepen understanding of the bioprocessing environment by means of insights on links between the process parameters and product characteristics. This helps one to grasp the bioprocessing environment better. Manufacturers may make use of this knowledge to create advanced control systems including feedback control loops or even model predictive control, therefore optimising the process performance and ensuring consistency of the product.

By means of PAT-enabled optimisation, which simplifies bioprocessing operations, it is feasible to simplify opportunities for process intensification as well as efficiency gains, thereby reducing cycle durations and increasing productivity. By always monitoring and modifying process parameters, manufacturers may minimise cycle times, boost throughput, and even raise general productivity. This enables their progressive progress and goal attainment.

PAT is in line with the ideas that apply to quality by design (QbD) since it helps to build solid processes that go on to produce things regularly with the necessary quality traits. This enables manufacturers to go forward and include quality into the process from the very start, therefore lowering the risk related to product failures and deviations. One achieves this by including PAT instruments into the phases of design and development.

Apart from a cut in waste, production expenses also reduce. By means of consistent monitoring and control made available by PAT, one may help identify and minimise process inefficiencies, therefore lowering the raw material, energy, and waste generation amounts. Consequently, not only does this save production costs, but it also aids in the accomplishment of sustainability targets by lessening environmental negative effects.

Regarding the facilitation of regulatory compliance, PAT gives manufacturers the tools and the data they need to present to regulatory authorities demonstrating that they have a complete awareness of the process, that they have control over it, and that they are consistent with it. Using PAT helps producers to simplify regulatory filings, speed up product approvals, and guarantee compliance with strict regulatory criteria.

All things considered; PAT-enabled optimization has a significant potential in the continuous bioprocessing industry. This possibility motivates manufacturers to achieve higher degrees of process efficiency, quality, and regulatory compliance, therefore generating more revenues.

In terms of ongoing bioprocessing, high production and cost promote chromatography system appeal.

Product into chromatography systems with filtering systems along with devices; consumables; bioreactors; cell lines, cell culture medium, buffers, and reagents; also, other products divide the market for consistent bioprocessing. This is something one ought to give thought. Among other components, the chromatography systems and the consumables comprise resins, membranes, buffers, solvents, columns, reagents, and other consumables like autosamplers, fittings, and tubing detectors. Consistent chromatography techniques are absolutely essential for continual downstream bioprocessing if one is to get high protein purity. These advanced techniques offer a lot of interesting possibilities. One can keep the process running constantly by running several chromatography columns either countercurrent or even concurrent. This is so because the loading is done in the first column and all the other subsequent processes—elution, regeneration, washing, and re-equilibration—occur inside the next columns. Many chromatographic methods are part of the continuous mode of operation. Countercurrent chromatography (CCT), multicolumn countercurrent solvent gradient purification chromatography (MCSGP), simulated moving bed (SMB) chromatography, and continuous annular chromatography (CAC) among these methods.

Growing demand for biologics has led to the necessity for intensification of the upstream bioprocess in order to raise production and minimise manufacturing costs. This is so due to the growing biologics market. Several studies by the National Centre for Biotechnology Information (NCBI) show how well integrated continuous bioprocessing is applied in manufacturing monoclonal antibodies (mAbs). These studies have indicated that the technique works. For example, one-column continuous chromatography (OCC) and perfusion bioreactor culture using alternative tangential flow technology (ATF) allowed a researcher to get about an eighty percent boost in productivity.

Moreover, companies are fast shifting their focus to chromatography systems in order to fulfil growing industry needs and speed their manufacturing processes. Following that, Waters Corporation and Sartorius AG announced in June of 2023 their cooperation to create integrated analytical solutions for the biomanufacturing process occurring deeper downstream.

The value of approaching farther downstream

Aimed at isolating and purifying the expected biopharmaceutical product from the complex mixture related to cellular components, media, and contaminants generated during upstream production, downstream processes have a sequence of purification steps along with separation techniques. Along with accessories and other products connected with them, these activities sometimes produce items such cell filtration systems, devices, chromatography systems, and consumables. Particularly continuous chromatography systems are reinventing downstream purification by enabling continuous separation as well as the purification of biopharmaceutical products with exceptional precision and throughput. This represents a major advancement in the downstream goods purification process. Large biopharmaceutical companies have effectively applied both aqueous two-phase extraction, also known as ATPS, and periodic countercurrent chromatography, also known as PCC, continuous CTC, MCSGP, and SMB for the aim of continuous capture from the process development scale all the way up to the manufacturing scale. These businesses have been able to avoid the possible process bottlenecks this suggests. These experts help to enhance the cost of the goods, the quality of the output, and the effectiveness of the process. Two among the several resins used in the Protein A resin screening process are MabSelect Sure PCC-Cytiva and Poros ProA-Thermo Fisher Scientific. These resins are reachable all during the process’s continuous capture phase. Apart from compound development and manufacturing companies (CDM), it is expected that more mid-sized biotech companies will arise in the next few years.

Some of the elements driving the high share of the segment in the market are the growing demand for biopharmaceuticals; rising technological advancements like single-pass tangential flow filtration and multicolumn chromatography; the increasing need for intensification of the downstream bioprocess as a result of an increased titer; and lowering production costs in the case of biosimilars and innovator drugs. These elements help the segment to have a significant market share.

An Application-Based Study of the Market for Ongoing Bioprocessing

Among the applications included in the consistent bioprocessing market segmentation are mAbs, vaccines, cell and gene therapy, and other ones. Application drives this segmentation of the market. It so happens that one of the most important subgroups of biotechnology medicine is monoclonal antibodies. The growing pharmaceutical research and development drug pipeline, the increasing emphasis on continuous bioprocessing in the manufacturing of monoclonal antibodies, the expanding clinical pipeline of monoclonal antibodies, and the growing regulatory approvals pertaining to therapeutic antibodies help to explain both the great share as well as the high growth rate inside this segment. These elements taken together have helped the segment to flourish.

Continuous bioprocessing is rapidly gaining speed in monoclonal antibody bioprocessing, so it has the potential to offer several advantages like smaller facility footprints, less investment costs, more flexibility, and economies of process. Once mammalian cell-derived monoclonal antibodies (mAbs) became commercially successful, demand for breakthrough single-use bioreactor systems surged. These technologies can reduce prices and provide far better degrees of flexibility and productivity. The successful proving of the viability of a completely integrated continuous process from the pilot size bioreactor to the therapeutic substance has led to research that has opened the road for its larger application within the industry.

Two more elements driving the growth of the market within this specific category are the increasing frequency of cancer and the growing necessity for cancer therapies. Monoclonal antibodies (mAbs) on the other hand have less side effects than chemotherapy. Another important factor driving the growth of the market is the emergence of new, more efficient and effective monoclonal antibody (mAbs) classes, such anti-PCSK9 monotherapy. Among the most effective monoclonal antibodies (mAbs), including Humira, Rituxan, Avastin, and Pembrolizumab-Keytruda, some have patents set to expire in the next few years. Patents have been lost, hence biopharmaceutical companies have been forced to proceed with including monoclonal antibodies (mAbs) into their drug manufacturing process. Regarding affordable solutions like continuous bioprocessing, demand is predicted to rise given the expanding pharmaceutical drug pipeline as well as the increasing number of regulatory approvals for the modular drug delivery systems (mABs).

Final Thoughts

Now leading the front stage in innovation is the constant bioprocessing sector, which will help to revolutionise manufacturing processes for pharmaceuticals worldwide. This is something one should give careful thought. Consistent bioprocessing provides advantages unmatched in terms of efficiency, productivity, and quality control when compared to conventional batch methods. This is so because continuous, smooth production flow of consistent bioprocessing is what drives An increasing demand for biopharmaceuticals, the rise of integrated end-to–end continuous bioprocessing, government and regulatory initiatives for favourable innovative technologies, and a rising acceptance among both contract manufacturing organisations (CMOs) and contract manufacturing organisations (CMOs) are driving the market under several angles. Indeed, the acceptance of continuous production techniques by pharmaceutical manufacturers is causing the market to develop fast and show diversity. Beginning with the upstream cell culture and fermentation operations and working all the way down to the downstream production processes of purification and formulation, continuous bioprocessing systems are applied across the whole biopharmaceutical manufacturing process. Furthermore adding to the improvement of process control and optimization—which finally yields higher efficiency and guarantees regulatory compliance—process analytical technology, sometimes referred to as PAT, in addition to automation.

With a compound annual growth rate of almost 8%, from $263 billion in 2022 to $566 billion by 2032, the value of the worldwide biopharmaceutical business is predicted to climb drastically.

Rising need for new treatments, chronic diseases, and growing incidence of technical innovation are largely driving this development.

Notable developments include the fast approval of monoclonal antibodies by authorities and the emergence of new medicines like gene and cell therapies, which are somewhat changing the range of treatments available for diseases like cancer and autoimmune disorders. High production costs and complicated regulatory requirements are two challenges the sector faces, nevertheless, which could also hinder the rapid development and perhaps commercialisation of biopharmaceutical products. Moreover, the great cost of biopharmaceutical treatments causes financial burden on patients that could impede market expansion since some patients would look for less expensive substitutes.

Two recent events that underlie the major investments and strategic alliances that have taken place in the sector are AstraZeneca’s licence agreement to develop monoclonal antibodies for COVID-19 treatment and Pfizer’s investment in Caribou Biosciences to advance allogeneic CAR-T cell therapy. These advances reflect the industry’s dedication to both creativity and filling in-demand medical demands.

Rising disease incidence and technological advancements are predicted to drive major development in the biopharmaceutical sector; yet, it will be necessary to overcome certain challenges concerning prices and regulations if it is to sustain its present growth trajectory.

The Principal Discoveries

Projected to be worth $566 billion by 2032, the global biopharmaceutical sector was anticipated to be valued at $263 billion, exerting a very significant market presence. This led to a great deal of expectations of them. Actually, until 2032 monoclonal antibodies are expected to govern the biopharmaceutical sector. But in 2022 the oncology category turned out to have the largest industry market share. Geographically, North America dominated the market with a gigantic 43% market share in 2022, largely due to government efforts and healthcare expenditure; Europe accounted for 23% of the worldwide market revenue.

Apart from this, the high population and government healthcare initiatives in the area of Asia Pacific resulted in substantial increase in this industry.

It is well known that deliberate cooperation of biopharma businesses and the increase in chronic diseases impede market expansion.

Furthermore, driving this sector are elements including COVID-19, the ageing population, and growing research budgets. Fascinatingly, a range of diseases like COVID-19 are treated with monoclonal antibodies and synthetic proteins. Three companies—J&J, Novo Nordisk, and Eli Lilly & Company—rule the biopharmaceutical industry.

As the first generics pharmaceutical manufacturer in Spain, Normon Laboratories has grown to be one of the most innovative and versatile pharmaceutical manufacturers in the industry. With high volumes of pharmaceuticals shipped throughout Spain and exported across the rest of the world, and offering additional contract manufacturing capabilities for customers in other markets, the company needed a serialization solution that could accommodate its various roles in the pharmaceutical supply chain and ensure compliance for its customers, as well as its own product lines. Normon selected TraceLink for its ability to scale at the enterprise level and its seamless integration with multiple contract manufacturing organizations, in order to enable compliance with the EU FMD serialization regulations.

“At Normon, we uphold our commitment to developing the safest and highest quality medicines at affordable prices for everyone. Our dedication to ensuring patient safety was a key factor in selecting a partner with a proven solution to comply with EU FMD,” said Gonzalo Fernández Govantes, Chief Operating Officer of Normon Laboratories. “We selected TraceLink for its demonstrated EU and country compliance capabilities and enterprise scalability. As Normon continues to expand its business through ongoing innovation, we are confident that TraceLink can provide the breadth of support needed in order for Normon to successfully comply with EU and global regulations.”

“We are pleased to be working with Normon Laboratories, a pioneer in the development of generic medications, and one of the leading pharmaceutical companies in Spain. At TraceLink, we understand and value the need to institute an EU FMD compliance strategy that can scale quickly to accommodate for rapid growth and impending deadlines for serialization and individual country compliance,” said Shabbir Dahod, president and CEO of TraceLink. “Drug traceability and serialization is a global initiative and we look forward to working closely with Normon Laboratories to meet the approaching EU FMD deadline for serialization and ultimately, help secure the integrity of their products for patients across Europe.”

With track and trace regulations that vary country to country and the impending EU FMD deadline in February 2019, life sciences companies face unprecedented complexity, cost and risk in how they implement serialization strategies. TraceLink has already processed EU compliance reports for more than 660,000 units of product into the European hub 17 months ahead of deadline. The TraceLink European Union Compliance module supports traceability reporting requirements from a single platform, providing customers with a tested integration to the European hub for reporting information about their product master data, serialized product pack data, and status changes for products targeted for distribution across all Member States.

To learn more about meeting global pharmaceutical compliance deadlines and how to build a flexible serialization, track and trace, and reporting platform, please visit www.tracelink.com.

About TraceLink
TraceLink is the World’s Largest Track and Trace Network for connecting the Life Sciences supply chain and eliminating counterfeit prescription drugs from the global marketplace. Leading businesses trust the TraceLink Life Sciences Cloud to deliver complete global connectivity, visibility and traceability of pharmaceuticals from ingredient to patient. A single point and click connection to the Life Sciences Cloud creates a supply chain control tower that delivers the information, insight and collaboration needed to improve performance and reduce risk across global supply, manufacturing and distribution operations. A winner of numerous industry awards including Deloitte’s Technology Fast 500 (ranked number 149 in 2016), the Amazon AWS Global Start-Up Challenge Grand Prize, and the Edison Award for Innovation in Health Management, the Life Sciences Cloud is used by businesses across the globe to meet strategic goals in ensuring global compliance, fighting drug counterfeiting, improving on-time and in-full delivery, protecting product quality and reducing operational cost. For more information on TraceLink and our solutions, visit www.tracelink.com

The acquisition of this Bloomington, Indiana-based biologics contract development and manufacturing organization substantially strengthens Catalent’s position as a leader in biologics development and analytical services, manufacturing and finished product supply. Their complementary capabilities and expertise will help customers accelerate biologic drug development programs and bring better treatments to patients worldwide.

Catalent intends to maximize the benefits of the acquisition through the reorganization of its operations to create two new dedicated business units that will sharpen the focus on growth, performance and customers’ needs.

First, recognizing the company’s substantially increased biopharmaceutical and fill-finish capabilities and the importance of the rapidly growing area of biologics, Catalent has created a business unit focused on Biologics & Specialty Drug Delivery, to be led by Barry Littlejohns as President. He will oversee eight Catalent facilities focused on biologics development, manufacturing, analytical, and sterile fill-finish and Catalent’s respiratory and ophthalmic business platforms. Tedd Green, formerly President of Cook Pharmica, will now serve as Senior Vice President, Catalent Bloomington.

Mr. Littlejohns has been with Catalent for 26 years, initially with its predecessor RP Scherer, and most recently served as President of the company’s former Drug Delivery Solutions business unit.
Second, Catalent has reorganized the remainder of its former Drug Delivery Solutions business into a newly formed Oral Drug Delivery business unit, to be led by Jonathan Arnold as President. Oral Drug Delivery will bring together Catalent’s expertise and capabilities in advanced delivery technologies and development solutions, including formulation and analytical development, bioavailability enhancement including micronization, hot melt extrusion and spray dry technologies, controlled release, Zydis® orally disintegrating tablet technology, and commercial supply across nine facilities.

Mr. Arnold has worked for leading life science organizations for over 23 years. These include RP Scherer, Patheon, and Catalent, where he has held senior business leadership roles in Europe and the U.S. For the past 6-years he has served as Vice President and General Manager for Catalent’s Drug Delivery Solutions business unit.

“The establishment of these focused business units reflects the rapid growth we are seeing across key markets, particularly for biologics and differentiated dosage forms,” commented John Chiminski, Chair and CEO of Catalent. “We have an exciting strategic plan to accelerate our portfolio of capabilities, as evidenced by the recent growth investments we have made, including multi-million-dollar site expansions and the newly completed acquisition of Cook Pharmica. We are confident that the experience and expertise of Barry, Jonathan, and Tedd will provide valuable leadership as we move forward in this exciting phase of our development.”

To arrange a meeting with Mr. Littlejohns or Mr. Arnold at CPhI in Frankfurt, please contact Richard Kerns, Northern Exposure PR at richard@nepr.eu.

Media Contacts:
Chris Halling
+44 (0)7580 041073
chris.halling@catalent.com

Richard Kerns
+44 (0) 161 728 5880
richard@nepr.eu

Investor Contact:
Thomas Castellano
+1 (732) 647 5013
thomas.castellano@catalent.com

ABOUT CATALENT
Catalent, Inc. , is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs over 10,000 people, including over 1,400 scientists, at more than 30 facilities across five continents, and in fiscal 2017 generated over $2 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com

“We evaluated Cotempla XR-ODT in a laboratory classroom study in children with ADHD and the data showed a statistically significant improvement in ADHD symptoms compared to placebo averaged across the classroom day,” said Andrew J. Cutler, MD, executive vice president and chief medical officer of Meridien Research in Tampa, Florida and a principal investigator in the Cotempla XR-ODT clinical studyi. “Onset of effect was evident at one hour post-dose and symptom control lasted through 12 hours. In addition, there was a 61% improvement in ADHD symptoms when treated with Cotempla XR-ODT at one hour versus baseline.”

No serious adverse events were reported during the trial, and the adverse events profile appears similar to the established tolerability profile for other extended-release methylphenidate products (most common adverse events for Cotempla XR-ODT are decreased appetite, trouble sleeping, nausea, vomiting, indigestion, stomach pain, weight loss, anxiety, dizziness, irritability, mood swings, increased heart rate, and increased blood pressure). Cotempla XR-ODT was approved by the US Food and Drug Administration (FDA) on June 19, 2017.

Cotempla XR-ODT is a federally controlled substance (CII) because it can be abused or lead to dependence. Keep Cotempla XR-ODT in a safe place to protect it from theft. Selling or giving away your Cotempla XR-ODT may cause death or harm to others and is against the law.

“We are very encouraged by the feedback we have been getting from physicians about Cotempla XR-ODT,” said Vipin K. Garg, Ph.D., president and chief excuetive officer of Neos Therapeutics. “With the availability of Cotempla XR-ODT, Adzenys XR-ODT (amphetamine) Extended-Release Orally Disintegrating Tablets, and the recent approval of Adzenys ER (amphetamine) Extended-Release Oral Suspension, Neos is providing physicians with additional options to help address the individual needs of their patients with ADHD.”

The study was conducted in 112 adult volunteers and used a controlled human infection model. According the study published in Lancet vaccine is safe, 100% immunogenic, and prevents up to 87% of infections, when using real life definitions of typhoid fever. Efficacy data from this trial will help to fill a long existing knowledge gap regarding Vi-conjugate vaccines.

This data is highly significant since the currently available vi-ps typhoid vaccines cannot be administered to children below 2 years, and do not confer long term immunity. Typbar-TCV can be administered to children below 2 years of age and does confer long term immunity. Protection over a longer term reduces the need for repeat vaccinations.

According to Dr. Krishna Ella chairman & managing director, Bharat Biotech the vaccine’s effectiveness endorses more than 10 years of R&D efforts and various clinical trials that have been carried out over the past 8 years. The company has built dedicated facilities for the manufacture of this vaccine. Typbar TCV conjugated to tetanus toxoid vaccine human challenge study holds great promise particularly in of south Asia and sub-Saharan Africa. The company is working with the Consortium in carrying out field trials in different countries to evaluate its efficacy.

“Multidrug-resistant Salmonella typhi has become a major public health problem, as antibiotics are prescribed antibiotics for even common fever in developing nations. Citing example of drug resistance against typhoid fever found in Hyderabad city in Pakistan, he said this paves way for an early realisation of an effective vaccine to reduce typhoid burden.

“We are proud being world-first to pursue a high risk human challenge study and be successful. The trial led by Prof. Andrew Pollard, Director, Oxford Vaccine Group, was designed based on human infection models where many of the participants, mostly University students, were to consume a drink containing bacteria. The trial results clearly show that the new Typhoid Conjugate vaccine gives significantly superior performance compared to the Typhoid Vi polysaccharide vaccine,” he added.

“Typhoid is preventable and its control should be a global health priority. We are pleased to support the Typhoid Vaccine Acceleration Consortium as part of our overall strategy to combat typhoid through an integrated approach including access to clean water, improved sanitation, and immunization, ” said Anita Zaidi, director, Enteric and Diarrheal Diseases team, Bill & Melinda Gates Foundation.

The Product Summary File is to World Health Organisation for prequalification which would allow for UNICEF to procure the vaccine for low-income countries where the disease burden is high. TypbarTCV is currently licensed in India, Nigeria, and Nepal, with registrations underway in Malaysia, Turkey, Thailand, Uganda, Kenya, Bangladesh, Pakistan, Vietnam, among 30 other countries.

The facility in Lisbon is the latest of Recipharm’s facilities to be prepared to start supplying serialised products to the US and Europe, following a EUR 40 million investment into its company-wide implementation programme in 2016.

Recipharm has already delivered over 1.3 million serialised and aggregated packs to markets such as, China, South Korea, Saudi Arabia and Turkey where serialisation regulations are currently in place. The Lisbon site is the sixth to become serialisation-ready for the US and European markets and adds an additional four packaging lines to the company’s current serialisation capabilities. This will be followed by a further seven lines at the facility by Q2 in 2018.

Staffan Widengren, Director of Corporate Projects at Recipharm and head of the global steering committee for Recipharm’s serialisation project said: “Recipharm recognised the complexity of implementing serialisation at a very early stage and so we’ve been preparing for the new regulations in the US and Europe for a long time now. The Lisbon facility brings us to over a third of the way through our implementation project and is an important milestone in our journey.”

“We introduced our serialisation programme to ensure a consistent roll-out of our standard solution, without the implementation process having a significant impact on production activities. It’s important our solution works at a local level, as well as company-wide, and the central team that heads up the programme is tasked with making this happen.”

“Effective serialisation capabilities can eventually help companies to improve their overall equipment effectiveness (OEE) and streamline their operations. The programme also helps us to ensure that serialisation data integrates with our enterprise resource planning (ERP) activity and our manufacturing execution systems (MES) so that we can achieve wider business benefits beyond compliance.”

The central team is responsible for identifying, ordering, installing and qualifying serialisation systems in line with customer requirements. The next site to be equipped will be the company’s facility in Brescia, which will supply serialised product to the US.

Recipharm’s serialisation programme was recently recognised in the TRACKTS Awards 2017 as an example of best practice for its execution of a track and trace system at the Lisbon facility following a detailed assessment of the project’s methodology, use of technology and innovation.

Contact information
Staffan Widengren,
Director Corporate Projects,
staffan.widengren@recipharm.com,
+46 8 6024 475

About Recipharm
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing around 5,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s turnover is approximately SEK 5.3 billion and the company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. 

About serialisation
Serialisation is a means to trace and track pharmaceuticals from manufacture through to prescription, using bar codes to record information about product origin, shelf life and batch. This will help the fight against counterfeit products entering the supply chain and ultimately improve patient safety.

The patent, entitled Method for prevention of colectomy (patent number 6193248), was filed in 2012 and will provide an exclusivity period until November 2032, with the possibility of up to 5 years term extension after market approval.

“We are very pleased with the granting of this patent by the Japan Patent Office, which again confirms that cobitolimod is a unique and innovative asset for treating ulcerative colitis,” said Peter Zerhouni, CEO of InDex Pharmaceuticals. “This patent further strengthens and extends our intellectual property position for cobitolimod in Japan, which is the second largest individual pharmaceutical market in the world.”

A corresponding patent was granted in the US in November 2016, and corresponding patent applications have also been filed in Europe and Canada and are being diligently prosecuted to grant.

For more information:
Peter Zerhouni, CEO
Phone: +46 8 508 847 35
E-mail: peter.zerhouni@indexpharma.com

Cobitolimod in brief
Cobitolimod is a new type of drug that can help patients with moderate to severe ulcerative colitis back to a normal life. It is a so-called Toll-like receptor 9 (TLR9) agonist, that can provide an anti-inflammatory effect locally in the large intestine, which may induce mucosal healing and relief of the clinical symptoms in ulcerative colitis. Cobitolimod has achieved clinical proof-of-concept in moderate to severe active ulcerative colitis, with a very favorable safety profile. Data from four placebo-controlled clinical trials indicate that cobitolimod has statistically significant effects on those endpoints that are most relevant in this disease, both from a regulatory and clinical perspective. These endpoints include the key clinical symptoms such as blood in stool, number of stools, and mucosal healing, respectively. Cobitolimod is also known as Kappaproct® and DIMS0150.

InDex Pharmaceuticals in brief
InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s foremost asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe active ulcerative colitis – a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases.

InDex is based in Stockholm, Sweden. The company’s shares are traded on Nasdaq First North Stockholm. Redeye AB is the company’s Certified Adviser. For more information, please visit www.indexpharma.com